Journal Logo

October 2020 - Volume 30 - Issue 5
pp: 429-531

Basic Science

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

Vidarsdottir, Linda; Fernandes, Rita Valador; Zachariadis, Vasilios; More

Melanoma Research. 30(5):443-454, October 2020.

Translational Research

Clinical Research

BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma

Cybulska-Stopa, Bozena; Rogala, Pawel; Czarnecka, Anna M.; More

Melanoma Research. 30(5):465-471, October 2020.

Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort

Dalmasso, Céline; Pagès, Cécile; Chaltiel, Léonor; More

Melanoma Research. 30(5):472-476, October 2020.

Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma

Sengul Samanci, Nilay; Çelik, Emir; Bagcilar, Omer; More

Melanoma Research. 30(5):477-483, October 2020.

MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project

Caini, Saverio; Gandini, Sara; Botta, Francesca; More

Melanoma Research. 30(5):500-510, October 2020.